# HistoSonics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/histosonics

- Industry: Medical Devices & Equipment
- Headquarters: Plymouth, US
- Website: www.histosonics.com/
- Total disclosed funding: $208M
- Latest round: Series D (Jul 31, 2024)
- Investors on record: 16

## About

Founded in 2009 and based in Minnesota, US, HistoSonics, Inc. operates as a medical device company that develops a non-invasive robotic platform to help reduce patient trauma and healthcare costs across multiple indications. The company's primary product includes the Edison® System, which is designed specifically for the non-invasive destruction of liver tumors. This approach utilizes focused ultrasound, generating high-amplitude, short pulses to create a bubble cloud that mechanically destroys and liquefies targeted liver tumors at a subcellular level. HistoSonics’ method is non-thermal and avoids the use of ionizing radiation, heat damage, and surgical incisions, offering a novel approach to treating liver tumors. In July 2026, HistoSonics, Inc. raised an undisclosed amount in venture funding from MPower. Individual investor also participated in this round. The company's primary product includes the Edison® System, which is designed specifically for the non-invasive destruction of liver tumors. This approach utilizes focused ultrasound, generating high-amplitude, short pulses to create a bubble cloud that mechanically destroys and liquefies targeted liver tumors at a subcellular level. HistoSonics’ method is non-thermal and avoids the use of ionizing radiation, heat damage, and surgical incisions, offering a novel approach to treating liver tumors. HistoSonics, Inc. generates revenue by selling its Edison histotripsy systems, associated disposables, and service packages to hospitals and clinics, while expanding income through new clinical indications, global market adoption, and ongoing technology-driven treatment utilization. In July 2026, HistoSonics, Inc. raised an undisclosed amount in venture funding from MPower. Individual investor also participated in this round. The company plans to utilize July 2026 funding to expand the commercialization of its non-invasive tumor treatment platform, advance clinical development for additional tumor indications, and support global market expansion.

## Funding rounds

- Series D, Jul 31, 2024, $102M — Venture Investors, State of Wisconsin Investment Board, Johnson & Johnson Innovation, Alpha Wave Global, HealthQuest Capital, Yonjin Venture, Amzak Capital Management, Lumira Ventures
- Series C, Jun 8, 2020, $40M — Venture Investors, State of Wisconsin Investment Board, Johnson & Johnson Innovation, Varian Medical Systems, Inc., Yonjin Venture, Lumira Ventures
- Series C, Apr 5, 2019, $47M — Venture Investors, State of Wisconsin Investment Board, Johnson & Johnson Innovation, Varian Medical Systems, Inc., Lumira Ventures
- Series B, Jan 30, 2017, $8.3M — Venture Investors, Fletcher Spaght Ventures, TGap Ventures, Hatteras Venture Partners, Early Stage Partners, Grand Angels, Wolverine Venture Fund, UM-MINTS
- Series A, Dec 21, 2009, $11M — Venture Investors, Fletcher Spaght Ventures, TGap Ventures, Hatteras Venture Partners, Early Stage Partners

## Investors

- Venture Investors — Series A, Series B, Series C, Series D
- Fletcher Spaght Ventures (https://capitalatlas.ai/funds/fletcher-spaght-ventures) — Series A, Series B
- TGap Ventures (https://capitalatlas.ai/funds/tgap-ventures) — Series A, Series B
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A, Series B
- Early Stage Partners (https://capitalatlas.ai/funds/early-stage-partners) — Series A, Series B
- Grand Angels — Series B
- Wolverine Venture Fund (https://capitalatlas.ai/funds/wolverine-venture-fund) — Series B
- UM-MINTS — Series B
- State of Wisconsin Investment Board — Series C, Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C, Series D
- Varian Medical Systems, Inc. — Series C
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series C, Series D
- Yonjin Venture (https://capitalatlas.ai/funds/yonjin-venture) — Series C, Series D
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series D
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series D
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series D